Briefly, 7/8 patients showed at least one single nucleotide variant (SNV) affecting SH2B3, 6/8 ASXL1 and TET2 genes, 3/8 TP53, 2/8 ETV6, FLT3, NF1, PTPN11, while 1/8 CEBPA, GATA2, IKZF1, KIT, PRPF8, RB1, and SF3B1. Despite not being reported as clinically relevant, those disrupting mutations occurred in genes well-known to be associated with myeloid malignancies; therefore, it is conceivable that they might have some pathogenic activity. The gene discussed is TP53; the disease is myeloid neoplasm.